| |
Article Title |
Author(s) |
Type |
Pages |
|
Patient-centered online management of psoriasis: A randomized controlled equivalency trial
June 2012 (Vol. 66 | No. 6 | Pages 948-953)
|
Cindy J. Chambers,
Kory K. Parsi,
Clayton Schupp,
April W. Armstrong
|
Full-length article
|
948-953
|
|
Association between pediatric psoriasis and the metabolic syndrome
June 2012 (Vol. 66 | No. 6 | Pages 1012-1013)
|
Shiu-chung Au,
Ari M. Goldminz,
Daniel S. Loo,
Nicole Dumont,
Danielle Levine,
Eva Volf,
Melissa Michelon,
Andrew Wang,
Noori Kim,
Shimrat Yaniv,
Paul F. Lizzul,
Todd Kerensky,
Jorge M. Lopez-Benitez,
Marc Natter,
Laurie Miller,
Christina F. Pelajo,
Trevor Davis,
Alice B. Gottlieb
et al.
|
Short communication
|
1012-1013
|
|
Psoriasis
June 2012 (Vol. 66 | No. 6 | Page e258)
|
Charles Camisa
|
Book review
|
e258-e258
|
|
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials
May 2012 (Vol. 66 | No. 5 | Pages 731-741)
|
Mark Lebwohl,
Craig Leonardi,
Christopher E.M. Griffiths,
Jörg C. Prinz,
Philippe O. Szapary,
Newman Yeilding,
Cynthia Guzzo,
Shu Li,
Ming-Chun Hsu,
Bruce Strober
et al.
|
Full-length article
|
731-741
|
|
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials
May 2012 (Vol. 66 | No. 5 | Pages 742-751)
|
Kenneth B. Gordon,
Kim A. Papp,
Richard G. Langley,
Vincent Ho,
Alexa B. Kimball,
Cynthia Guzzo,
Newman Yeilding,
Philippe O. Szapary,
Steven Fakharzadeh,
Shu Li,
Ming-Chun Hsu,
Kristian Reich
et al.
|
Full-length article
|
742-751
|
|
The role of antinuclear autoantibodies in patients with psoriasis treated with anti–tumor necrosis factor-alpha agents: A retrospective long-term study
May 2012 (Vol. 66 | No. 5 | Pages e180-e182)
|
Rosita Saraceno,
Francesca Specchio,
Tiago Torres,
Steven Paul Nisticò,
Stefano Rizza,
Sergio Chimenti
et al.
|
Short communication
|
e180-e182
|
|
A high serum concentration of chemerin in pustular dermatitis paradoxically induced by etanercept
May 2012 (Vol. 66 | No. 5 | Pages e182-e184)
|
Yu Sawada,
Motonobu Nakamura,
Kayo Hama,
Ryosuke Hino,
Yoshiki Tokura
et al.
|
Short communication
|
e182-e184
|
|
Treatment of psoriasis with rituximab
May 2012 (Vol. 66 | No. 5 | Pages e184-e185)
|
Yu-Sheng Chang,
Hui-Ting Lee,
Wei-Sheng Chen,
Kai-Hung Hsiao,
Ming-Han Chen,
Chang-Youh Tsai,
Chung-Tei Chou
et al.
|
Short communication
|
e184-e185
|
|
Cost-effectiveness analysis of a patient-centered care model for management of psoriasis
April 2012 (Vol. 66 | No. 4 | Pages 563-570)
|
Kory Parsi,
Cindy J. Chambers,
April W. Armstrong
|
Full-length article
|
563-570
|
|
The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: A 30-year prospective study
April 2012 (Vol. 66 | No. 4 | Pages 553-562)
|
Robert S. Stern,
PUVA Follow-Up Study
|
Full-length article
|
553-562
|
|
A review of targeted ultraviolet B phototherapy for psoriasis
April 2012 (Vol. 66 | No. 4 | Pages 664-672)
|
Tejaswi Mudigonda,
Tushar S. Dabade,
Steven R. Feldman
|
Review article
|
664-672
|
|
Leflunomide in dermatology
April 2012 (Vol. 66 | No. 4 | Pages 673-679)
|
Alan S. Boyd
|
Review article
|
673-679
|
|
Response to the letter to editor re: “Methotrexate and psoriasis: Consensus conference”
April 2012 (Vol. 66 | No. 4 | Page 689)
|
Alan Menter
|
Correspondence
|
689-689
|
|
Methotrexate and psoriasis: Consensus conference
April 2012 (Vol. 66 | No. 4 | Pages 689-690)
|
Robert E. Kalb,
Bruce Strober,
Gerald Weinstein,
Mark Lebwohl
|
Correspondence
|
689-690
|
|
Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis
March 2012 (Vol. 66 | No. 3 | Pages 369-375)
|
Amanda Robinson,
Marisa Kardos,
Alexandra B. Kimball
|
Full-length article
|
369-375
|
|
Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients
March 2012 (Vol. 66 | No. 3 | Pages 376-386)
|
Joy Wan,
Katrina Abuabara,
Andrea B. Troxel,
Daniel B. Shin,
Abby S. Van Voorhees,
Bruce F. Bebo,
Gerald G. Krueger,
Kristina Callis Duffin,
Joel M. Gelfand
et al.
|
Full-length article
|
376-386
|
|
Live attenuated varicella vaccine: A new effective adjuvant weapon in the battlefield against severe resistant psoriasis, a pilot randomized controlled trial
March 2012 (Vol. 66 | No. 3 | Pages 511-513)
|
Mohammad A. El-Darouti,
Rehab A. Hegazy,
Rania M. Abdel Hay,
Dalia M. Abdel Halim
|
Short communication
|
511-513
|
|
The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis
February 2012 (Vol. 66 | No. 2 | Pages e67-e76)
|
Alexa Boer Kimball,
Andrew P. Yu,
James Signorovitch,
Jipan Xie,
Magda Tsaneva,
Shiraz R. Gupta,
Yanjun Bao,
Parvez M. Mulani
et al.
|
Full-length article
|
e67-e76
|
|
Psoriasis and cardiovascular risk factors: A case-control study on inpatients comparing psoriasis to dermatitis
February 2012 (Vol. 66 | No. 2 | Pages 252-258)
|
Jonathan Shapiro,
Arnon David Cohen,
Dahlia Weitzman,
Roy Tal,
Michael David
et al.
|
Full-length article
|
252-258
|
|
Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL
February 2012 (Vol. 66 | No. 2 | Pages 241-251)
|
Kenneth Gordon,
Kim Papp,
Yves Poulin,
Yihua Gu,
Stephen Rozzo,
Eric H. Sasso
et al.
|
Full-length article
|
241-251
|
